Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

Related Clinical Trial
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

Official Title

Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study

Brief Summary

      The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic
      strategy for remission induction in patients with Eosinophilic Granulomatosis with

Detailed Description

      Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome,
      is a rare systemic small-vessel vasculitis, associated with asthma and blood and tissue
      eosinophilia. EGPA belongs to the group of antineutrophil cytoplasmic antibody
      (ANCA)-associated vasculitides (AAV), and commonly involves upper and lower respiratory
      tracts, the lungs, the peripheral nerve and the heart.

      Therapeutic management is based on glucocorticoids alone or in combination with conventional
      immunosuppressive agents, mainly azathioprine, methotrexate or cyclophosphamide, according to
      disease severity assessed by the Five Factor Score.

      Such treatments, in addition to their common side effects, are frequently insufficiently
      effective to control chronic asthma and/or rhinosinusitis, requiring long-term high-dose
      corticosteroids. Because EGPA shares common pathophysiological features with eosinophilic
      disorders and asthma, new therapeutic options used in these conditions could be of interest,
      in particular mepolizumab, a monoclonal anti-interleukin (IL)-5 antibody, which has shown
      promising results in two small preliminary studies to control disease activity and decrease
      glucocorticoids in cortico-dependant patients. In addition, mepolizumab has been recently
      evaluated in a prospective trial, the MIRRA trial, targeting a small niche of patients, i.e.
      those with corticodependent asthma unable to achieve disease control with low dose of
      glucocorticoids. Results published revealed that mepolizumab led to significantly more
      accrued weeks of remission than placebo (28% vs. 3% of the participants had ≥24 weeks of
      accrued remission; odds ratio, 5.91; 95% confidence interval [CI], 2.68 to 13.03; P<0.001)
      and a higher percentage of participants in remission at both week 36 and week 48 (32% vs. 3%;
      odds ratio, 16.74; 95% CI, 3.61 to 77.56; P<0.001).

      However, these studies did not evaluate the interest of mepolizumab during EGPA flare
      associating asthma, eosinophilic and vasculitis lesions, in order to induce remission of the
      disease and rapidly decrease and discontinue glucocorticoids.

      Also, recent pathophysiological date strongly support in addition to previous therapeutic
      studies the major interest to target IL-5 as soon as EGPA is diagnosed: 1) genetic
      association studies demonstrated that polymorphisms in the IL-5 pathway are associated with
      EGPA in comparison with controls, 2) increased expression of IL-5 in mice model are able to
      induce vasculitis lesions as observed in the human diseases.

      Patients will receive a standardized glucocorticoid tapering schedule. From day 28
      post-baseline onwards, if the subject's BVAS=0 their oral prednisone dose should be tapered
      downwards. A standardized glucocorticoid tapering schedule provided in the protocol enables a
      reduction in oral prednisone dose every 2 weeks, with the intention of achieving a prednisone
      dose of 4 mg/day or less. Once a subject has achieved a dose of 4 mg/day prednisone, the
      investigator is encouraged to continue tapering downwards, if clinically warranted, at dose
      increments of 1.0 mg every week.

      Upwards dose adjustments within the 0-4.0 mg range are permitted without necessarily being
      considered a relapse.

Study Phase

Phase 3

Study Type


Primary Outcome

Percentage of patients who achieved a prednisone dose of 4.0 mg or less per day at day 168, without experiencing a relapse

Secondary Outcome

 Prednisone dosage at days 168 and 364


Eosinophilic Granulomatosis With Polyangiitis



Study Arms / Comparison Groups

 Patients with FFS=0 - Mepolizumab
Description:  Mepolizumab 300mg every 4 weeks until D336


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 30, 2022

Completion Date

May 2025

Primary Completion Date

May 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with a diagnosis of EGPA independently of ANCA status,

          -  Patients aged of 18 years or older,

          -  Patients with newly-diagnosed disease or relapsing disease at the time of screening,
             with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥3,

          -  Patients within the first 21 days following initiation/increase of corticosteroids at
             a dose ≤ 1 mg/kg/day (pulses of methylprednisolone before oral corticosteroid therapy
             are authorized)

          -  Patients having given their written informed consent prior to participation in the

          -  Patients affiliated with social security or CMU (profit or being entitled)

        Exclusion Criteria:

          -  Patients with GPA, MPA, or other vasculitis, defined by the ACR criteria and/or the
             Chapel Hill Consensus Conference,

          -  Patients with vasculitis in remission of the disease defined as a BVAS <3

          -  Patients with severe cardiac failure defined as class IV in New York Heart Association

          -  Patients with acute infections or chronic active infections (including HIV, HBV or HCV
             and checked in the last 12 months),

          -  Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma
             and prostatic cancer of low activity controlled by hormonal treatment,

          -  Pregnant women and lactation. Patients with childbearing potential should have
             reliable contraception for the 12 months duration of the study,

          -  Patients with EGPA who have already been treated with mepolizumab within the previous
             12 months,

          -  Patients with hypersensitivity to a monoclonal antibody or biologic agent,

          -  Patients with contraindication to use mepolizumab, cyclophosphamide, mesna,
             azathioprine or maintenance therapy used for vasculitis,

          -  Patients with other uncontrolled diseases, including drug or alcohol abuse, severe
             psychiatric diseases, that could interfere with participation in the trial according
             to the protocol,

          -  Patients included in other investigational therapeutic study within the previous 3

          -  Patients suspected not to be observant to the proposed treatments,

          -  Patients who have white blood cell count ≤4,000/mm3,

          -  Patients who have platelet count ≤100,000/mm3,

          -  Patients who have ALT or AST level greater that 3 times the upper limit of normal that
             cannot be attributed to underlying EGPA disease,

          -  Patients unable to give written informed consent prior to participation in the study

          -  Patients under tutorship or curatorship and protected adults.




18 Years - N/A

Accepts Healthy Volunteers



Loic GUILLEVIN, MD, PhD, (+33)1 58 41 14 61, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Assistance Publique - Hôpitaux de Paris


 French Vasculitis Study Group

Study Sponsor

Loic GUILLEVIN, MD, PhD, Study Director, Assistance Publique - Hôpitaux de Paris

Verification Date

June 2022